CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Biomimetic lymph node-like scaffolds for optimized CAR-T cell expansion and potentiated antitumor efficacy.
Biomimetic lymph node-like scaffolds for optimized CAR-T cell expansion and potentiated antitumor efficacy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T 细胞疗法在治疗血液系统恶性肿瘤方面展现出显著前景。然而,CAR-T 细胞的体外扩增耗时较长,可能损害其功能。生理条件下,T细胞在淋巴结(LN)副皮质区活化和增殖;该动态环境由三维(3D)网状网络(RN)构成,可促进细胞迁移和介质递送。模拟这一生理微环境为改善CAR-T 细胞扩增提供了有吸引力的策略。受RN结构启发,我们开发了仿生RN样多孔微球(PM),建立适用于T细胞和CAR-T 细胞增殖的三维培养平台。与传统方法相比,该工程化系统显著提高了人T细胞和CAR-T 细胞的增殖率,同时保留了较高比例的中央记忆T细胞(TCM),并降低耗竭标志物(PD-1、TIM-3和LAG-3)的表达。
此外,在PM中扩增的CAR-T 细胞在离体和体内模型中均展现出更强的抗肿瘤效力,这与RNA水平上富集了稳健T细胞功能相关通路相一致。
总体而言,这一仿生平台解决了人T/CAR-T 细胞扩增中的关键局限,有助于维持细胞功能并改善治疗结局。
Chimeric antigen receptor T cell (CAR-T) therapy has shown remarkable promise in treating hematological malignancies.
However, the ex vivo expansion of CAR-T cells is time-consuming, potentially impairing CAR-T cell function. Physiologically, T cell activation and proliferation occur within the lymph node (LN) paracortex, a dynamic environment structured by a three-dimensional (3D) reticular network (RN) that promotes cell migration and mediator delivery. Mimicking this physiological niche offers a compelling strategy to improve CAR-T cell expansion.
Inspired by the structure of the RN, we developed a biomimetic RN-like poriferous microsphere (PM) to establish a 3D culture platform optimized for both T cell and CAR-T cell proliferation. This engineered system not only significantly enhanced the proliferation rates of human T cells and CAR-T cells compared to conventional methods, but also preserved a higher proportion of central memory T cells (T CM ) and reduced the expression of exhaustion markers (PD-1, TIM-3, and LAG-3).
Moreover, CAR-T cells expanded in PMs exhibited superior anti-tumor efficacy in both ex vivo and in vivo models, which correlated with the enrichment of pathways associated with robust T cell function at the RNA level.
Overall, this biomimetic platform addresses critical limitations in human T/CAR-T cell expansion, preserving cell function and improving therapeutic outcomes.
MEMBER ACCOUNT
登录成功会直接打开下一页。